Brand Name, Dosage Format and Strength
Cardepine 10 mg/10 mL Solution for Injection
Cardiovascular and Hematopoietic System
Angiotensin-Converting Enzyme Inhibitor, Angiotensin-Converting Enzyme Inhibitor, Diuretic, Angiotensin-II Receptor Blocker, Angiotensin-II Receptor Blocker, Diuretic, 3-Ketoacyl Coenzyme A Thiolase (3-KAT) Inhibitor, Nitrates Salicylate, Antiplatelet, Peripheral Vasodilator, Beta-Andrenoceptor Blocker, Calcium Channel Blocker, Direct-acting Inotropic Agent, Diuretic, Angiotensin-Converting Enzyme Inhibitor, Diuretic, Angiotensin-II Receptor Blocker, Diuretic, Fibric Acid Derivative, HMG-CoA Reductase Inhibitor, Recombinant Human Erythropoietin, Hemostatics
INTERACTION/S WITH OTHER MEDICAMENTS
Beta-blockers (e.g., propranolol): β-blockers result in an excessive decrease in BP and a reduction in cardiac function in patients with CHF. Reduce dosage or discontinue use of either drug when necessary.
Cimetidine: Cimetidine increases nicardipine plasma levels. Patients receiving the two drugs concomitantly should be carefully monitored.
Digoxin: Nicardipine may increase plasma levels of digitalis preparations. Evaluate digoxin levels when concomitant therapy with nicardipine IV is initiated.
Fentanyl anesthesia: Concomitant use of fentanyl anesthesia with a calcium channel blocker has been reported to cause hypotension. Although such interactions were not seen in studies with nicardipine IV, an increased volume of circulating fluids might be necessary in the occurrence of such interactions.
Ciclosporin: Concomitant administration increases ciclosporin plasma levels. Ciclosporin dosage should therefore be reduced accordingly in patients treated with nicardipine.
Other antihypertensive agents: Monitor patients to identify and treat promptly any undesirable effects from concomitant administration
In vitro interaction: No changes in plasma protein binding of nicardipine were observed when furosemide, propranolol, dipyridamole, warfarin, quinidine, or naproxen were added to human plasma in vitro.